Amitriptyline Explained

Watchedfields:changed
Verifiedrevid:477169407
Image Class:skin-invert-image
Width:200
Width2:250
Pronounce:[1]
Tradename:Elavil, others
Dailymedid:Amitriptyline
Pregnancy Au:C
Pregnancy Au Comment:[2]
Routes Of Administration:Oral, intramuscular injection
Class:Tricyclic antidepressant (TCA)
Atc Prefix:N06
Atc Suffix:AA09
Legal Au:S4
Legal Br:C1
Legal Br Comment:[3]
Legal Ca:Rx-only
Legal Uk:POM
Legal Us:Rx-only
Bioavailability:45%-53%
Protein Bound:96%
Metabolism:Liver (CYP2D6, CYP2C19, CYP3A4)
Metabolites:nortriptyline, (E)-10-hydroxynortriptyline
Elimination Half-Life:21 hours
Excretion:Urine

12–80% after 48 hours; feces: not studied

Cas Number:50-48-6
Cas Supplemental:
549-18-8 (hydrochloride)
17086-03-2 (embonate)
Pubchem:2160
Iuphar Ligand:200
Drugbank:DB00321
Chemspiderid:2075
Unii:1806D8D52K
Kegg:D07448
Chebi:2666
Chembl:629
Iupac Name:3-(10,11-dihydro-5H-dibenzo[''a'',''d'']cycloheptene-5-ylidene)-N,N-dimethylpropan-1-amine
C:20
H:23
N:1
Smiles:c3cc2c(/C(c1c(cccc1)CC2)=C\CCN(C)C)cc3
Stdinchi:1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
Stdinchikey:KRMDCWKBEZIMAB-UHFFFAOYSA-N
Melting Point:197.5
Melting Notes:[4]

Amitriptyline, sold under the brand name Elavil among others, is a tricyclic antidepressant primarily used to treat major depressive disorder, and a variety of pain syndromes such as neuropathic pain, fibromyalgia, migraine and tension headaches.[5] Due to the frequency and prominence of side effects, amitriptyline is generally considered a second-line therapy for these indications.

The most common side effects are dry mouth, drowsiness, dizziness, constipation, and weight gain. Glaucoma, liver toxicity and abnormal heart rhythms are rare but serious side effects. Blood levels of amitriptyline vary significantly from one person to another,[6] and amitriptyline interacts with many other medications potentially aggravating its side effects.

Amitriptyline was discovered in the late 1950s by scientists at Merck and approved by the US Food and Drug Administration (FDA) in 1961.[7] It is on the World Health Organization's List of Essential Medicines.[8] It is available as a generic medication.[9] In 2022, it was the 87th most commonly prescribed medication in the United States, with more than 7million prescriptions.[10] [11]

Medical uses

Amitriptyline is indicated for the treatment of major depressive disorder, neuropathic pain, and for the prevention of migraine and chronic tension headache. It can be used for the treatment of nocturnal enuresis in children older than 6 after other treatments have failed.[5]

Depression

Amitriptyline is effective for depression, but it is rarely used as a first-line antidepressant due to its higher toxicity in overdose and generally poorer tolerability.[12] It can be tried for depression as a second-line therapy, after the failure of other treatments.[13] For treatment-resistant adolescent depression[14] or for cancer-related depression[15] amitriptyline is no better than placebo; however, the number of treated patients in both studies was small. It is sometimes used for the treatment of depression in Parkinson's disease,[16] but supporting evidence for that is lacking.[17]

Pain

Amitriptyline alleviates painful diabetic neuropathy. It is recommended by a variety of guidelines as a first or second-line treatment.[18] It is as effective for this indication as gabapentin or pregabalin but less well tolerated.[19] Amitriptyline is as effective at relieving pain as duloxetine. Combination treatment of amitriptyline and pregabalin offers additional pain relief for people whose pain is not adequately controlled with one medication and is usually safe.[20] [21] Amitriptyline in certain formulations may also induce the level of sciatic-nerve blockade needed for local anesthesia therein.[22] Here, it has been demonstrated to be of superior potency to bupivacaine, a customary long-acting local anesthetic.

Low doses of amitriptyline moderately improve sleep disturbances and reduce pain and fatigue associated with fibromyalgia. It is recommended for fibromyalgia accompanied by depression by Association of the Scientific Medical Societies in Germany[23] and as a second-line option for fibromyalgia, with exercise being the first line option, by European League Against Rheumatism.[24] Combinations of amitriptyline and fluoxetine or melatonin may reduce fibromyalgia pain better than either medication alone.[25]

There is some (low-quality) evidence that amitriptyline may reduce pain in cancer patients. It is recommended only as a second-line therapy for non-chemotherapy-induced neuropathic or mixed neuropathic pain if opioids did not provide the desired effect.[26]

Moderate evidence exists in favor of amitriptyline use for atypical facial pain.[27] Amitriptyline is ineffective for HIV-associated neuropathy.[19]

In multiple sclerosis, it is frequently used to treat painful paresthesias in the arms and legs (e.g., burning sensations, pins and needles, stabbing pains) caused by damage to the pain-regulating pathways of the brain and spinal cord.[28]

Headache

Amitriptyline is probably effective for the prevention of periodic migraine in adults. Amitriptyline is similar in efficacy to venlafaxine and topiramate but carries a higher burden of adverse effects than topiramate.[29] For many patients, even very small doses of amitriptyline are helpful, which may allow for minimization of side effects.[30] Amitriptyline is not significantly different from placebo when used for the prevention of migraine in children.[31]

Amitriptyline may reduce the frequency and duration of chronic tension headache, but it is associated with worse adverse effects than mirtazapine. Overall, amitriptyline is recommended for tension headache prophylaxis, along with lifestyle advice, which should include avoidance of analgesia and caffeine.[32]

Other indications

Amitriptyline is effective for the treatment of irritable bowel syndrome; however, because of its side effects, it should be reserved for select patients for whom other agents do not work.[33] [34] [35] There is insufficient evidence to support its use for abdominal pain in children with functional gastrointestinal disorders.[36]

Tricyclic antidepressants decrease the frequency, severity, and duration of cyclic vomiting syndrome episodes. Amitriptyline, as the most commonly used of them, is recommended as a first-line agent for its therapy.[37]

Amitriptyline may improve pain and urgency intensity associated with bladder pain syndrome and can be used in the management of this syndrome.[38] [39] Amitriptyline can be used in the treatment of nocturnal enuresis in children. However, its effect is not sustained after the treatment ends. Alarm therapy gives better short- and long-term results.[40]

In the US, amitriptyline is commonly used in children with ADHD as an adjunct to stimulant medications without any evidence or guideline supporting this practice.[41] Many physicians in the UK (and the US also) commonly prescribe amitriptyline for insomnia;[42] however, Cochrane reviewers were not able to find any randomized controlled studies that would support or refute this practice.[43] Similarly, a major systematic review and network meta-analysis of medications for the treatment of insomnia published in 2022 found little evidence to inform the use of amitriptyline for insomnia.[44] The well-known sedating effects of amitriptyline, however, bear understanding on and arguable justification for this practice. It may function similarly to doxepin in this regard, although the evidence for doxepin is more robust.[45] Trimipramine may be a more novel alternative given its tendency to not suppress but brighten R.E.M. sleep.[46] [47] [48]

Contraindications and precautions

The known contraindications of amitriptyline are:[5]

Amitriptyline should be used with caution in patients with epilepsy, impaired liver function, pheochromocytoma, urinary retention, prostate enlargement, hyperthyroidism, and pyloric stenosis.[5]

In patients with the rare condition of shallow anterior chamber of eyeball and narrow anterior chamber angle, amitriptyline may provoke attacks of acute glaucoma due to dilation of the pupil. It may aggravate psychosis, if used for depression with schizophrenia. It may precipitate the switch to mania in those with bipolar disorder.[49]

CYP2D6 poor metabolizers should avoid amitriptyline due to increased side effects. If it is necessary to use it, half dose is recommended.[50] Amitriptyline can be used during pregnancy and lactation when SSRIs have been shown not to work.[51]

Side effects

The most frequent side effects, occurring in 20% or more of users, are dry mouth, drowsiness, dizziness, constipation, and weight gain (on average 1.8 kg[52]).[53] Other common side effects are headache problems (amblyopia, blurred vision), tachycardia, increased appetite, tremor, fatigue/asthenia/feeling slowed down, and dyspepsia.[53]

A less common side effect of amitriptyline is urination problems (8.7%).[53]

Amitriptyline can increase suicidal thoughts and behavior in people under the age of 24 and the US FDA required a boxed warning to be added to the prescription label.[54] Amitriptyline-associated sexual dysfunction (occurring at a frequency of 6.9%) seems to be mostly confined to males with depression and is expressed predominantly as erectile dysfunction and low libido disorder, with lesser frequency of ejaculatory and orgasmic problems. The rate of sexual dysfunction in males treated for indications other than depression and in females is not significantly different from placebo.[55]

Liver test abnormalities occur in 10–12% of patients on amitriptyline, but are usually mild, asymptomatic, and transient, with consistently elevated alanine transaminase in 3% of all patients.[56] [57] The increases of the enzymes above the 3-fold threshold of liver toxicity are uncommon, and cases of clinically apparent liver toxicity are rare;[58] nevertheless, amitriptyline is placed in the group of antidepressants with greater risks of hepatic toxicity.[56]

Amitriptyline prolongs the QT interval.[59] This prolongation is relatively small at therapeutic doses[60] but becomes severe in overdose.[61]

Overdose

See main article: Tricyclic antidepressant overdose. The symptoms and the treatment of an overdose are largely the same as for the other TCAs, including the presentation of serotonin syndrome and adverse cardiac effects. The British National Formulary notes that amitriptyline can be particularly dangerous in overdose,[62] thus it and other TCAs are no longer recommended as first-line therapy for depression. The treatment of overdose is mostly supportive as no specific antidote for amitriptyline overdose is available. Activated charcoal may reduce absorption if given within 1–2 hours of ingestion. If the affected person is unconscious or has an impaired gag reflex, a nasogastric tube may be used to deliver the activated charcoal into the stomach. ECG monitoring for cardiac conduction abnormalities is essential and if one is found close monitoring of cardiac function is advised. Body temperature should be regulated with measures such as heating blankets if necessary. Cardiac monitoring is advised for at least five days after the overdose. Benzodiazepines are recommended to control seizures. Dialysis is of no use due to the high degree of protein binding with amitriptyline.[63]

Interactions

Since amitriptyline and its active metabolite nortriptyline are primarily metabolized by cytochromes CYP2D6 and CYP2C19 (see its pharmacology), the inhibitors of these enzymes are expected to exhibit pharmacokinetic interactions with amitriptyline. According to the prescribing information, the interaction with CYP2D6 inhibitors may increase the plasma level of amitriptyline.[5] However, the results in the other literature are inconsistent:[64] the co-administration of amitriptyline with a potent CYP2D6 inhibitor paroxetine does increase the plasma levels of amitriptyline two-fold and of the main active metabolite nortriptyline 1.5-fold,[65] but combination with less potent CYP2D6 inhibitors thioridazine or levomepromazine does not affect the levels of amitriptyline and increases nortriptyline by about 1.5-fold;[66] A case of clinically significant interaction with potent CYP2D6 inhibitor terbinafine has been reported.[67]

A potent inhibitor of CYP2C19 and other cytochromes fluvoxamine increases the level of amitriptyline two-fold while slightly decreasing the level of nortriptyline.[68] Similar changes occur with a moderate inhibitor of CYP2C19 and other cytochromes cimetidine: amitriptyline level increases by about 70%, while nortriptyline decreases by 50%.[69] CYP3A4 inhibitor ketoconazole elevates amitriptyline level by about a quarter.[70] On the other hand, cytochrome P450 inducers such as carbamazepine and St. John's Wort decrease the levels of both amitriptyline and nortriptyline[66] [71]

Oral contraceptives may increase the blood level of amitriptyline by as high as 90%.[72] Valproate moderately increases the levels of amitriptyline and nortriptyline through an unclear mechanism.[73]

The prescribing information warns that the combination of amitriptyline with monoamine oxidase inhibitors may cause potentially lethal serotonin syndrome;[5] however, this has been disputed.[74] The prescribing information cautions that some patients may experience a large increase in amitriptyline concentration in the presence of topiramate. However, other literature states that there is little or no interaction: in a pharmacokinetic study topiramate only increased the level of amitriptyline by 20% and nortriptyline by 33%.[75]

Amitriptyline counteracts the antihypertensive action of guanethidine.[63] [76] When given with amitriptyline, other anticholinergic agents may result in hyperpyrexia or paralytic ileus.[77] Co-administration of amitriptyline and disulfiram is not recommended due to the potential for the development of toxic delirium.[63] [78] Amitriptyline causes an unusual type of interaction with the anticoagulant phenprocoumon during which great fluctuations of the prothrombin time have been observed.[79]

Pharmacology

Pharmacodynamics

See also: Pharmacology of antidepressants.

Molecular targets of amitriptyline (AMI) and main active metabolite nortriptyline (NTI)[80]
Site Species Ref
2.8–36 15–279 Human [81] [82]
19–102 1.8–21 Human
3,250 1,140 Human
450–1,800 294 Human [83] [84]
840 Rat [85]
18–23 41 Human
174 Human [86]
4-8 8.5 Rat [87] [88]
430 1,400 Rat [89]
65–141 148 Human/rat [90] [91] [92]
92.8–123 Rat [93]
6.5–25 18–37 Human [94] [95]
600–1700850–1300Human
560 1500 Human
114–690 2,030 Human
88 Human [96]
>1000 Human
120 Human
>10,000 >10,000 Rat [97]
89 210 (rat) Human/rat
196–1,460 2,570 Human
206 Human
170 Human
0.5–1.1 3.0–15 Human [98] [99] [100]
66 646 Human
75,900;>1000 45,700 Human
34–26,300 6,920 Human [101]
11.0–14.7 40 Human [102] [103]
11.8 110 Human
12.8–39 50 Human
7.2 84 Human
15.7–24 97 Human
287–300 2,000 Guinea pig/rat [104] [105]
3,260 31,600 Human [106] [107]
1650 Human [108]
3,000
(agonist) 		Human [109]
14,000
(agonist) 		Human
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.

Amitriptyline inhibits serotonin transporter (SERT) and norepinephrine transporter (NET). It is metabolized to nortriptyline, a stronger norepinephrine reuptake inhibitor, further augmenting amitriptyline's effects on norepinephrine reuptake (see table in this section).

Amitriptyline additionally acts as a potent inhibitor of the serotonin 5-HT2A, 5-HT2C, the α1A-adrenergic, the histamine H1 and the M1-M5 muscarinic acetylcholine receptors (see table in this section).

Amitriptyline is a non-selective blocker of multiple ion channels, in particular, voltage-gated sodium channels Nav1.3, Nav1.5, Nav1.6, Nav1.7, and Nav1.8,[110] [111] [112] voltage-gated potassium channels Kv7.2/ Kv7.3,[113] Kv7.1, Kv7.1/KCNE1,[114] and hERG.[106]

Mechanism of action

Inhibition of serotonin and norepinephrine transporters by amitriptyline results in interference with neuronal reuptake of serotonin and norepinephrine. Since the reuptake process is important physiologically in terminating transmitting activity, this action may potentiate or prolong the activity of serotonergic and adrenergic neurons and is believed to underlie the antidepressant activity of amitriptyline.[77]

Inhibition of norepinephrine reuptake leads to an increased concentration of norepinephrine in the posterior gray column of the spinal cord appears to be mostly responsible for the analgesic action of amitriptyline. Increased level of norepinephrine increases the basal activity of alpha-2 adrenergic receptors, which mediate an analgesic effect by increasing gamma-aminobutyric acid transmission among spinal interneurons. The blocking effect of amitriptyline on sodium channels may also contribute to its efficacy in pain conditions.[115]

Pharmacokinetics

Amitriptyline is readily absorbed from the gastrointestinal tract (90–95%).[115] Absorption is gradual with the peak concentration in blood plasma reached after about 4 hours.[116] Extensive metabolism on the first pass through the liver leads to average bioavailability of about 50% (45%[116] -53%[115]). Amitriptyline is metabolized mostly by CYP2C19 into nortriptyline and by CYP2D6 leading to a variety of hydroxylated metabolites, with the principal one among them being (E)-10-hydroxynortriptyline (see metabolism scheme),[115] and to a lesser degree, by CYP3A4.

Nortriptyline, the main active metabolite of amitriptyline, is an antidepressant on its own right. Nortriptyline reaches 10% higher level in the blood plasma than the parent drug amitriptyline and 40% greater area under the curve, and its action is an important part of the overall action of amitriptyline.[116] [64]

Another active metabolite is (E)-10-hydroxynortriptyline, which is a norepinephrine uptake inhibitor four times weaker than nortriptyline. (E)-10-hydroxynortiptyline blood level is comparable to that of nortriptyline, but its cerebrospinal fluid level, which is a close proxy of the brain concentration of a drug, is twice higher than nortriptyline's. Based on this, (E)-10-hydroxynortriptyline was suggested to significantly contribute to the antidepressant effects of amitriptyline.[117]

Blood levels of amitriptyline and nortriptyline and pharmacokinetics of amitriptyline in general, with clearance difference of up to 10-fold, vary widely between individuals.[118] Variability of the area under the curve in steady state is also high, which makes a slow upward titration of the dose necessary.[6]

In the blood, amitriptyline is 96% bound to plasma proteins; nortriptyline is 93–95% bound, and (E)-10-hydroxynortiptyline is about 60% bound.[63] [119] [117] Amitriptyline has an elimination half life of 21 hours,[116] nortriptyline – 23–31 hours,[120] and (E)-10-hydroxynortiptyline − 8–10 hours.[117] Within 48 hours, 12−80% of amitriptyline is eliminated in the urine, mostly as metabolites.[121] 2% of the unchanged drug is excreted in the urine.[122] Elimination in the feces, apparently, have not been studied.

Therapeutic levels of amitriptyline range from 75 to 175 ng/mL (270–631 nM),[123] or 80–250 ng/mL of both amitriptyline and its metabolite nortriptyline.[124]

Pharmacogenetics

Since amitriptyline is primarily metabolized by CYP2D6 and CYP2C19, genetic variations within the genes coding for these enzymes can affect its metabolism, leading to changes in the concentrations of the drug in the body.[125] Increased concentrations of amitriptyline may increase the risk for side effects, including anticholinergic and nervous system adverse effects, while decreased concentrations may reduce the drug's efficacy.[126] [127] [128] [129]

Individuals can be categorized into different types of CYP2D6 or CYP2C19 metabolizers depending on which genetic variations they carry. These metabolizer types include poor, intermediate, extensive, and ultrarapid metabolizers. Most individuals (about 77–92%) are extensive metabolizers,[50] and have "normal" metabolism of amitriptyline. Poor and intermediate metabolizers have reduced metabolism of the drug as compared to extensive metabolizers; patients with these metabolizer types may have an increased probability of experiencing side effects. Ultrarapid metabolizers use amitriptyline much faster than extensive metabolizers; patients with this metabolizer type may have a greater chance of experiencing pharmacological failure.[126] [127] [50]

The Clinical Pharmacogenetics Implementation Consortium recommends avoiding amitriptyline in patients who are CYP2D6 ultrarapid or poor metabolizers, due to the risk of a lack of efficacy and side effects, respectively. The consortium also recommends considering an alternative drug not metabolized by CYP2C19 in patients who are CYP2C19 ultrarapid metabolizers. A reduction in the starting dose is recommended for patients who are CYP2D6 intermediate metabolizers and CYP2C19 poor metabolizers. If the use of amitriptyline is warranted, therapeutic drug monitoring is recommended to guide dose adjustments.[50] The Dutch Pharmacogenetics Working Group also recommends selecting an alternative drug or monitoring plasma concentrations of amitriptyline in patients who are CYP2D6 poor or ultrarapid metabolizers, and selecting an alternative drug or reducing initial dose in patients who are CYP2D6 intermediate metabolizers.[130]

Chemistry

Amitriptyline is a highly lipophilic molecule having an octanol-water partition coefficient (pH 7.4) of 3.0,[131] while the log P of the free base was reported as 4.92.[132] Solubility of the free base amitriptyline in water is 14 mg/L.[133] Amitriptyline is prepared by reacting dibenzosuberane with 3-(dimethylamino)propylmagnesium chloride and then heating the resulting intermediate product with hydrochloric acid to eliminate water.[115]

History

Amitriptyline was first developed by the American pharmaceutical company Merck in the late 1950s. In 1958, Merck approached several clinical investigators proposing to conduct clinical trials of amitriptyline for schizophrenia. One of these researchers, Frank Ayd, instead, suggested using amitriptyline for depression. Ayd treated 130 patients and, in 1960, reported that amitriptyline had antidepressant properties similar to another, and the only known at the time, tricyclic antidepressant imipramine.[134] Following this, the US Food and Drug Administration approved amitriptyline for depression in 1961.[7]

In Europe, due to a quirk of the patent law at the time allowing patents only on the chemical synthesis but not on the drug itself, Roche and Lundbeck were able to independently develop and market amitriptyline in the early 1960s.[135]

According to research by a historian of psychopharmacology David Healy, amitriptyline became a much bigger selling drug than its precursor imipramine because of two factors. First, amitriptyline has a much stronger anxiolytic effect. Second, Merck conducted a marketing campaign raising clinicians' awareness of depression as a clinical entity.[135] [134]

Society and culture

In the 2021 film The Many Saints of Newark, amitriptyline (referred to by the brand name Elavil) is part of the plot line of the movie.[136]

Names

Amitriptyline is the English and French generic name of the drug and its,, and, while amitriptyline hydrochloride is its,,, and .[137] [138] [139] [140] Its generic name in Spanish and Italian and its are Spanish; Castilian: amitriptilina, in German is German: Amitriptylin, and in Latin is Latin: amitriptylinum. The embonate salt is known as amitriptyline embonate, which is its BANM, or as amitriptyline pamoate unofficially.

Prescription trends

Between 1998 and 2017, along with imipramine, amitriptyline was the most commonly prescribed first antidepressant for children aged 5–11 years in England. It was also the most prescribed antidepressant (along with fluoxetine) for 12- to 17-year-olds.[141]

Research

The few randomized controlled trials investigating amitriptyline efficacy in eating disorder have been discouraging.[142]

See also

Further reading

Notes and References

  1. Web site: Amitriptyline . https://web.archive.org/web/20140714140116/http://www.oxforddictionaries.com/us/definition/english/amitriptyline?q=amitriptyline . dead . Oxford Dictionary . Lexico.com . 14 July 2014 . en . 6 January 2021.
  2. Web site: Amitriptyline Use During Pregnancy . Drugs.com . 2 September 2020 . 13 September 2020 . 9 November 2020 . https://web.archive.org/web/20201109214320/https://www.drugs.com/pregnancy/amitriptyline.html . live .
  3. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  4. Blessel KW, Rudy BC, Senkowski BZ . Amitriptyline Hydrochloride . Analytical Profiles of Drug Substances . 3 . 127–148 . 1974 . 10.1016/S0099-5428(08)60066-0. 9780122608032 .
  5. Web site: Amitriptyline Tablets BP 50mg – Summary of Product Characteristics (SPC). electronic Medicines Compendium. Actavis UK Ltd.. 24 March 2013. 1 December 2013. live. https://web.archive.org/web/20131203015148/http://www.medicines.org.uk/emc/medicine/23738/SPC/Amitriptyline+Tablets+BP+50mg/. 3 December 2013.
  6. Tfelt-Hansen P, Ågesen FN, Pavbro A, Tfelt-Hansen J . Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine . CNS Drugs . 31 . 5 . 389–403 . May 2017 . 28405886 . 10.1007/s40263-017-0430-3 . 23560743 .
  7. Fangmann P, Assion HJ, Juckel G, González CA, López-Muñoz F . Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics . Journal of Clinical Psychopharmacology . 28 . 1 . 1–4 . February 2008 . 18204333 . 10.1097/jcp.0b013e3181627b60 . 31018835 .
  8. Book: ((World Health Organization)) . The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) . 2023 . 10665/371090 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2023.02 . free .
  9. Web site: Amitriptyline Hydrochloride. The American Society of Health-System Pharmacists. Drugs.com. 25 September 2014. live. https://web.archive.org/web/20140924185142/http://www.drugs.com/monograph/amitriptyline-hydrochloride.html. 24 September 2014.
  10. Web site: The Top 300 of 2022 . ClinCalc . 30 August 2024 . 30 August 2024 . https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  11. Web site: Amitriptyline Drug Usage Statistics, United States, 2013 - 2022 . ClinCalc . 30 August 2024 . 30 April 2017 . https://web.archive.org/web/20170430155658/https://clincalc.com/DrugStats/Drugs/Amitriptyline . live .
  12. Book: Australian Medicines Handbook . 2013 . The Australian Medicines Handbook Unit Trust . 978-0-9805790-9-3 . 2013 . Adelaide . Rossi S .
  13. Book: Hitchings A, Lonsdale D, Burrage D, Baker E . Top 100 drugs : clinical pharmacology and practical prescribing . 2015 . 978-0-7020-5516-4 . 50. Churchill Livingstone .
  14. Zhou X, Michael KD, Liu Y, Del Giovane C, Qin B, Cohen D, Gentile S, Xie P . Systematic review of management for treatment-resistant depression in adolescents . BMC Psychiatry . 14 . 340 . November 2014 . 25433401 . 4254264 . 10.1186/s12888-014-0340-6 . free .
  15. Riblet N, Larson R, Watts BV, Holtzheimer P . Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis . General Hospital Psychiatry . 36 . 5 . 466–473 . 2014 . 24950919 . 10.1016/j.genhosppsych.2014.05.010 .
  16. Web site: Parkinson's disease. merckmanuals.com. https://web.archive.org/web/20131118154550/http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/movement_disorders/parkinsons_disease.html . 18 November 2013 . Merck Sharp & Dohme Corp.. August 2007. 22 December 2013.
  17. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C . The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease . Movement Disorders . 26 . Supply 3 . S42–S80 . October 2011 . 22021174 . 4020145 . 10.1002/mds.23884 .
  18. Alam U, Sloan G, Tesfaye S . Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs . Drugs . 80 . 4 . 363–384 . March 2020 . 32040849 . 10.1007/s40265-020-01259-2 . 211074023 .
  19. Liampas A, Rekatsina M, Vadalouca A, Paladini A, Varrassi G, Zis P . Pharmacological Management of Painful Peripheral Neuropathies: A Systematic Review . Pain and Therapy . 10 . 1 . 55–68 . June 2021 . 33145709 . 8119529 . 10.1007/s40122-020-00210-3 . free .
  20. 6 April 2023 . Combination therapy for painful diabetic neuropathy is safe and effective . NIHR Evidence . en . 10.3310/nihrevidence_57470 . 258013544 . 28 April 2023 . 28 April 2023 . https://web.archive.org/web/20230428104720/https://evidence.nihr.ac.uk/alert/combination-therapy-for-painful-diabetic-neuropathy-is-safe-and-effective/ . live .
  21. Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, Jude EB, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsatlidis V, Johnson M, Rice AS, Bouhassira D, Bennett DL, Selvarajah D . Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial . Lancet . 400 . 10353 . 680–690 . August 2022 . 36007534 . 9418415 . 10.1016/s0140-6736(22)01472-6 .
  22. Sudoh Y, Cahoon EE, Gerner P, Wang GK . Tricyclic antidepressants as long-acting local anesthetics . Pain . 103 . 1–2 . 49–55 . May 2003 . 12749958 . 10.1016/s0304-3959(02)00375-5 . 24955042 .
  23. Sommer C, Alten R, Bär KJ, Bernateck M, Brückle W, Friedel E, Henningsen P, Petzke F, Tölle T, Üçeyler N, Winkelmann A, Häuser W . [Drug therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles] . de . Schmerz . 31 . 3 . 274–284 . June 2017 . 28493231 . 10.1007/s00482-017-0207-0 . 195671256 .
  24. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT . EULAR revised recommendations for the management of fibromyalgia . Annals of the Rheumatic Diseases . 76 . 2 . 318–328 . February 2017 . 27377815 . 10.1136/annrheumdis-2016-209724 . free . free . 2164/8814 .
  25. Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I . Combination pharmacotherapy for the treatment of fibromyalgia in adults . The Cochrane Database of Systematic Reviews . 2 . 2 . CD010585 . February 2018 . 29457627 . 6491103 . 10.1002/14651858.CD010585.pub2 .
  26. van den Beuken-van Everdingen MH, de Graeff A, Jongen JL, Dijkstra D, Mostovaya I, Vissers KC . Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review . Pain Practice . 17 . 3 . 409–419 . March 2017 . 27207115 . 10.1111/papr.12459 . 37418010 .
  27. Do TM, Unis GD, Kattar N, Ananth A, McCoul ED . Neuromodulators for Atypical Facial Pain and Neuralgias: A Systematic Review and Meta-Analysis . The Laryngoscope . 131 . 6 . 1235–1253 . June 2021 . 33037835 . 10.1002/lary.29162 . 222256076 .
  28. Web site: Elavil for MS . 7 July 2023 . nationalmssociety.org . 7 July 2023 . https://web.archive.org/web/20230707205228/https://www.nationalmssociety.org/Treating-MS/Medications/Elavil . dead .
  29. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E . Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society . Neurology . 78 . 17 . 1337–1345 . April 2012 . 22529202 . 3335452 . 10.1212/WNL.0b013e3182535d20 .
  30. Loder E, Rizzoli P . Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018 . Headache . 58 . Suppl 3 . 218–229 . November 2018 . 30137671 . 10.1111/head.13375 . 52071815 .
  31. Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, Holler-Managan Y, Leininger E, Licking N, Mack K, Powers SW, Sowell M, Victorio MC, Yonker M, Zanitsch H, Hershey AD . Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society . Neurology . 93 . 11 . 500–509 . September 2019 . 31413170 . 6746206 . 10.1212/WNL.0000000000008105 .
  32. Ghadiri-Sani M, Silver N . Headache (chronic tension-type) . BMJ Clinical Evidence . 2016 . February 2016 . 26859719 . 4747324 .
  33. Trinkley KE, Nahata MC . Medication management of irritable bowel syndrome . Digestion . 89 . 4 . 253–267 . 2014 . 24992947 . 10.1159/000362405 . free .
  34. Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, Bianco G, Bishop FL, Chaddock M, Cook H, Cooper D, Fernandez C, Guthrie EA, Hartley S, Herbert A, Howdon D, Muir DP, Nath T, Newman S, Smith T, Taylor CA, Teasdale EJ, Thornton R, Farrin AJ, Everitt HA . Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial . Lancet . 402 . 10414 . 1773–1785 . November 2023 . 37858323 . 10.1016/s0140-6736(23)01523-4 . free .
  35. 26 March 2024 . Irritable bowel syndrome: low-dose antidepressant improves symptoms . NIHR Evidence . National Institute for Health and Care Research (NIHR) . 10.3310/nihrevidence_62555 . 12 April 2024 . 18 May 2024 . https://web.archive.org/web/20240518164652/https://evidence.nihr.ac.uk/alert/irritable-bowel-syndrome-low-dose-antidepressant-improves-symptoms/ . live .
  36. de Bruijn CM, Rexwinkel R, Gordon M, Benninga M, Tabbers MM . Antidepressants for functional abdominal pain disorders in children and adolescents . The Cochrane Database of Systematic Reviews . 2 . 2 . CD008013 . February 2021 . 33560523 . 8094232 . 10.1002/14651858.CD008013.pub3 .
  37. Venkatesan T, Levinthal DJ, Tarbell SE, Jaradeh SS, Hasler WL, Issenman RM, Adams KA, Sarosiek I, Stave CD, Sharaf RN, Sultan S, Li BU . Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association . Neurogastroenterology and Motility . 31 . Suppl 2 . e13604 . June 2019 . 31241819 . 6899751 . 10.1111/nmo.13604 .
  38. Giusto LL, Zahner PM, Shoskes DA . An evaluation of the pharmacotherapy for interstitial cystitis . Expert Opinion on Pharmacotherapy . 19 . 10 . 1097–1108 . July 2018 . 29972328 . 10.1080/14656566.2018.1491968 . 49674883 .
  39. Colemeadow J, Sahai A, Malde S . Clinical Management of Bladder Pain Syndrome/Interstitial Cystitis: A Review on Current Recommendations and Emerging Treatment Options . Research and Reports in Urology . 12 . 331–343 . 2020 . 32904438 . 7455607 . 10.2147/RRU.S238746 . free .
  40. Caldwell PH, Sureshkumar P, Wong WC . Tricyclic and related drugs for nocturnal enuresis in children . The Cochrane Database of Systematic Reviews . 2016 . 1 . CD002117 . January 2016 . 26789925 . 8741207 . 10.1002/14651858.CD002117.pub2 .
  41. Klein T, Woo TM, Panther S, Odom-Maryon T, Daratha K . Somnolence-Producing Agents: A 5-Year Study of Prescribing for Medicaid-Insured Children With Attention Deficit Hyperactivity Disorder . Journal of Pediatric Health Care . 33 . 3 . e1–e8 . 2019 . 30630642 . 10.1016/j.pedhc.2018.10.002 . 58577978 .
  42. Everitt H, McDermott L, Leydon G, Yules H, Baldwin D, Little P . GPs' management strategies for patients with insomnia: a survey and qualitative interview study . The British Journal of General Practice . 64 . 619 . e112–e119 . February 2014 . 24567616 . 3905408 . 10.3399/bjgp14X677176 .
  43. Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CC, Wilson S . Antidepressants for insomnia in adults . The Cochrane Database of Systematic Reviews . 2018 . 5 . CD010753 . May 2018 . 29761479 . 6494576 . 10.1002/14651858.CD010753.pub2 .
  44. De Crescenzo F, D'Alò GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, Kurtulmus A, Tomlinson A, Mitrova Z, Foti F, Del Giovane C, Quested DJ, Cowen PJ, Barbui C, Amato L, Efthimiou O, Cipriani A . Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis . Lancet . 400 . 10347 . 170–184 . July 2022 . 35843245 . 10.1016/S0140-6736(22)00878-9 . free . 250536370 . free . 11380/1288245 .
  45. Atkin T, Comai S, Gobbi G . Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery . Pharmacological Reviews . 70 . 2 . 197–245 . April 2018 . 29487083 . 10.1124/pr.117.014381 .
  46. Pecknold JC, Luthe L . Trimipramine, anxiety, depression and sleep . Drugs . 38 . Suppl 1 . 25–31; discussion 49–50 . 1989 . 2693052 . 10.2165/00003495-198900381-00007 .
  47. Riemann D, Voderholzer U, Cohrs S, Rodenbeck A, Hajak G, Rüther E, Wiegand MH, Laakmann G, Baghai T, Fischer W, Hoffmann M, Hohagen F, Mayer G, Berger M . Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study . Pharmacopsychiatry . 35 . 5 . 165–74 . September 2002 . 12237787 . 10.1055/s-2002-34119 .
  48. Berger M, Gastpar M . Trimipramine: a challenge to current concepts on antidepressives . European Archives of Psychiatry and Clinical Neuroscience . 246 . 5 . 235–9 . 1996 . 8863001 . 10.1007/BF02190274 .
  49. Koszewska I, Rybakowski JK . Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs . Neuropsychobiology . 59 . 1 . 12–16 . 2009 . 19221443 . 3689226 . 10.1159/000202824 .
  50. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC . Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants . Clinical Pharmacology and Therapeutics . 93 . 5 . 402–408 . May 2013 . 23486447 . 3689226 . 10.1038/clpt.2013.2 .
  51. Nielsen RE, Damkier P . Pharmacological treatment of unipolar depression during pregnancy and breast-feeding--a clinical overview . Nordic Journal of Psychiatry . 66 . 3 . 159–166 . June 2012 . 22283766 . 10.3109/08039488.2011.650198 . 11327135 .
  52. Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH . Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis . The Journal of Clinical Endocrinology and Metabolism . 100 . 2 . 363–370 . February 2015 . 25590213 . 5393509 . 10.1210/jc.2014-3421 .
  53. Leucht C, Huhn M, Leucht S . Amitriptyline versus placebo for major depressive disorder . The Cochrane Database of Systematic Reviews . 2012 . 12. CD009138 . December 2012 . 23235671 . 10.1002/14651858.CD009138.pub2 . 11299154 .
  54. Book: StatPearls . Thour A, Marwaha R . 18 July 2023 . StatPearls Publishing . Treasure Island, Florida . Amitriptyline . 30725910 . 18 March 2024 . https://www.ncbi.nlm.nih.gov/books/NBK537225/ . 22 April 2024 . https://web.archive.org/web/20240422020545/https://ncbi.nlm.nih.gov/books/NBK537225/ . live .
  55. Chen LW, Chen MY, Lian ZP, Lin HS, Chien CC, Yin HL, Chu YH, Chen KY . Amitriptyline and Sexual Function: A Systematic Review Updated for Sexual Health Practice . American Journal of Men's Health . 12 . 2 . 370–379 . March 2018 . 29019272 . 5818113 . 10.1177/1557988317734519 .
  56. Voican CS, Corruble E, Naveau S, Perlemuter G . Antidepressant-induced liver injury: a review for clinicians . The American Journal of Psychiatry . 171 . 4 . 404–415 . April 2014 . 24362450 . 10.1176/appi.ajp.2013.13050709 .
  57. Holmberg MB . A study of blood count and serum transaminase in prolonged treatment with amitriptyline . The Journal of New Drugs . 2 . 6 . 361–365 . 1962 . 13961401 . 10.1177/009127006200200606 .
  58. Book: Amitriptyline. 6 January 2012. National Institute of Diabetes and Digestive and Kidney Diseases. 6 January 2021. PubMed. 31643729. 21 January 2022. https://web.archive.org/web/20220121040521/https://www.ncbi.nlm.nih.gov/books/NBK548410/. live.
  59. Zemrak WR, Kenna GA . Association of antipsychotic and antidepressant drugs with Q-T interval prolongation . American Journal of Health-System Pharmacy . 65 . 11 . 1029–1038 . June 2008 . 18499875 . 10.2146/ajhp070279 . live . https://web.archive.org/web/20161221095718/http://www.medscape.com/viewarticle/575632_5 . 21 December 2016 .
  60. Hefner G, Hahn M, Hohner M, Roll SC, Klimke A, Hiemke C . QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients . Pharmacopsychiatry . 52 . 1 . 38–43 . January 2019 . 29466824 . 10.1055/s-0044-102009 . 3447931 .
  61. Campleman SL, Brent J, Pizon AF, Shulman J, Wax P, Manini AF . Drug-specific risk of severe QT prolongation following acute drug overdose . Clinical Toxicology . 58 . 12 . 1326–1334 . December 2020 . 32252558 . 7541562 . 10.1080/15563650.2020.1746330 .
  62. Book: Joint Formulary Committee . British National Formulary (BNF) . 2013 . 978-0-85711-084-8 . 65th . London, UK . Pharmaceutical Press . registration .
  63. Web site: Endep Amitriptyline hydrochloride. 10 December 2012. 1 December 2013. PDF. TGA eBusiness Services. Alphapharm Pty Limited. live. https://web.archive.org/web/20170813145944/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04558-3. 13 August 2017.
  64. Breyer-Pfaff U . The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man . Drug Metabolism Reviews . 36 . 3–4 . 723–746 . October 2004 . 15554244 . 10.1081/dmr-200033482 . 25565048 .
  65. Leucht S, Hackl HJ, Steimer W, Angersbach D, Zimmer R . Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients . Psychopharmacology . 147 . 4 . 378–383 . January 2000 . 10672631 . 10.1007/s002130050006 . 22476829 .
  66. Jerling M, Bertilsson L, Sjöqvist F . The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline . Therapeutic Drug Monitoring . 16 . 1 . 1–12 . February 1994 . 7909176 . 10.1097/00007691-199402000-00001 . 1428027 .
  67. Castberg I, Helle J, Aamo TO . Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline . Therapeutic Drug Monitoring . 27 . 5 . 680–682 . October 2005 . 16175144 . 10.1097/01.ftd.0000175910.68539.33 .
  68. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, Sechter D, Bizouard P . Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients . Pharmacological Research . 31 . 6 . 347–353 . June 1995 . 8685072 . 10.1016/1043-6618(95)80088-3 .
  69. Curry SH, DeVane CL, Wolfe MM . Cimetidine interaction with amitriptyline . European Journal of Clinical Pharmacology . 29 . 4 . 429–433 . 1985 . 3912187 . 10.1007/BF00613457 . 25430195 .
  70. Venkatakrishnan K, Schmider J, Harmatz JS, Ehrenberg BL, von Moltke LL, Graf JA, Mertzanis P, Corbett KE, Rodriguez MC, Shader RI, Greenblatt DJ . Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies . Journal of Clinical Pharmacology . 41 . 10 . 1043–1054 . October 2001 . 11583471 . 10.1177/00912700122012634 . 27146286 .
  71. Johne A, Schmider J, Brockmöller J, Stadelmann AM, Störmer E, Bauer S, Scholler G, Langheinrich M, Roots I . Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum) . Journal of Clinical Psychopharmacology . 22 . 1 . 46–54 . February 2002 . 11799342 . 10.1097/00004714-200202000-00008 . 25670895 .
  72. Berry-Bibee EN, Kim MJ, Simmons KB, Tepper NK, Riley HE, Pagano HP, Curtis KM . Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review . Contraception . 94 . 6 . 650–667 . December 2016 . 27444984 . 10.1016/j.contraception.2016.07.011 . 11283812 .
  73. Wong SL, Cavanaugh J, Shi H, Awni WM, Granneman GR . Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics . Clinical Pharmacology and Therapeutics . 60 . 1 . 48–53 . July 1996 . 8689811 . 10.1016/S0009-9236(96)90166-6 . 37720622 .
  74. Gillman PK . A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action . Biological Psychiatry . 59 . 11 . 1046–1051 . June 2006 . 16460699 . 10.1016/j.biopsych.2005.11.016 . 12179122 .
  75. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S . Pharmacokinetic interactions of topiramate . Clinical Pharmacokinetics . 43 . 12 . 763–780 . 2004 . 15355124 . 10.2165/00003088-200443120-00001 . 10427097 .
  76. Meyer JF, McAllister CK, Goldberg LI . Insidious and prolonged antagonism of guanethidine by amitriptyline . JAMA . 213 . 9 . 1487–1488 . August 1970 . 5468457 . 10.1001/jama.1970.03170350053016 .
  77. Web site: AMITRIPTYLINE HYDROCHLORIDE tablet, coated . DailyMed . 24 May 2024 . 30 September 2024.
  78. Maany I, Hayashida M, Pfeffer SL, Kron RE . Possible toxic interaction between disulfiram and amitriptyline . Archives of General Psychiatry . 39 . 6 . 743–744 . June 1982 . 7092508 . 10.1001/archpsyc.1982.04290060083018 .
  79. Web site: CHAPTER 132 ORAL ANTICOAGULATION | Free Medical Textbook . 9 February 2012 . 2 February 2021 . 27 September 2020 . https://web.archive.org/web/20200927103658/https://medtextfree.wordpress.com/2012/02/09/chapter-132-oral-anticoagulation/ . live .
  80. Web site: PDSP Ki Database . Psychoactive Drug Screening Program (PDSP) . Bryan Roth . Roth BL, Driscol J . University of North Carolina at Chapel Hill and the United States National Institute of Mental Health . 14 August 2017 . 27 August 2021 . https://web.archive.org/web/20210827213623/https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=amitriptyline&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query . live .
  81. Tatsumi M, Groshan K, Blakely RD, Richelson E . Pharmacological profile of antidepressants and related compounds at human monoamine transporters . European Journal of Pharmacology . 340 . 2–3 . 249–258 . December 1997 . 9537821 . 10.1016/s0014-2999(97)01393-9 .
  82. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB . Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites . The Journal of Pharmacology and Experimental Therapeutics . 283 . 3 . 1305–1322 . December 1997 . 9400006 .
  83. Cusack B, Nelson A, Richelson E . Binding of antidepressants to human brain receptors: focus on newer generation compounds . Psychopharmacology . 114 . 4 . 559–565 . May 1994 . 7855217 . 10.1007/bf02244985 . 21236268 .
  84. Peroutka SJ . Antimigraine drug interactions with serotonin receptor subtypes in human brain . Annals of Neurology . 23 . 5 . 500–504 . May 1988 . 2898916 . 10.1002/ana.410230512 . 41570165 .
  85. Peroutka SJ . Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex . Journal of Neurochemistry . 47 . 2 . 529–540 . August 1986 . 2942638 . 10.1111/j.1471-4159.1986.tb04532.x . 25108290 .
  86. Schmuck K, Ullmer C, Kalkman HO, Probst A, Lubbert H . Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache? . The European Journal of Neuroscience . 8 . 5 . 959–967 . May 1996 . 8743744 . 10.1111/j.1460-9568.1996.tb01583.x . 19578349 .
  87. Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J . Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor . Psychopharmacology . 126 . 3 . 234–240 . August 1996 . 8876023 . 10.1007/bf02246453 . 24889381 .
  88. Sánchez C, Hyttel J . Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding . Cellular and Molecular Neurobiology . 19 . 4 . 467–489 . August 1999 . 10379421 . 10.1023/a:1006986824213 . 19490821 .
  89. Schmidt AW, Hurt SD, Peroutka SJ . '[3H]quipazine' degradation products label 5-HT uptake sites . European Journal of Pharmacology . 171 . 1 . 141–143 . November 1989 . 2533080 . 10.1016/0014-2999(89)90439-1 . free .
  90. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, Meltzer HY, Sibley DR, Roth BL, Hamblin MW . Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor . Journal of Neurochemistry . 66 . 1 . 47–56 . January 1996 . 8522988 . 10.1046/j.1471-4159.1996.66010047.x . 35874409 .
  91. Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, Medhurst AD . Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling . Molecular Pharmacology . 64 . 6 . 1295–1308 . December 2003 . 14645659 . 10.1124/mol.64.6.1295 . 33743899 .
  92. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR . Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs . Molecular Pharmacology . 43 . 3 . 320–327 . March 1993 . 7680751 .
  93. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR . Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype . The Journal of Biological Chemistry . 268 . 24 . 18200–18204 . August 1993 . 8394362 . 10.1016/S0021-9258(17)46830-X . free .
  94. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS . The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors . Neuropharmacology . 59 . 1–2 . 49–57 . 2010 . 20363235 . 10.1016/j.neuropharm.2010.03.015 . 207225294 .
  95. Proudman RG, Pupo AS, Baker JG . The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors . Pharmacology Research & Perspectives . 8 . 4 . e00602 . August 2020 . 32608144 . 7327383 . 10.1002/prp2.602 .
  96. Fallarero A, Pohjanoksa K, Wissel G, Parkkisenniemi-Kinnunen UM, Xhaard H, Scheinin M, Vuorela P . High-throughput screening with a miniaturized radioligand competition assay identifies new modulators of human α2-adrenoceptors . European Journal of Pharmaceutical Sciences . 47 . 5 . 941–951 . December 2012 . 22982401 . 10.1016/j.ejps.2012.08.021 .
  97. Bylund DB, Snyder SH . Beta adrenergic receptor binding in membrane preparations from mammalian brain . Molecular Pharmacology . 12 . 4 . 568–580 . July 1976 . 8699 .
  98. von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H . Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics . Bioorganic & Medicinal Chemistry Letters . 19 . 2 . 538–542 . January 2009 . 19091563 . 10.1016/j.bmcl.2008.09.012 .
  99. Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R . Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics . Naunyn-Schmiedeberg's Archives of Pharmacology . 385 . 2 . 145–170 . February 2012 . 22033803 . 10.1007/s00210-011-0704-0 . 14274150 .
  100. Ghoneim OM, Legere JA, Golbraikh A, Tropsha A, Booth RG . Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes . Bioorganic & Medicinal Chemistry . 14 . 19 . 6640–6658 . October 2006 . 16782354 . 10.1016/j.bmc.2006.05.077 .
  101. Nguyen T, Shapiro DA, George SR, Setola V, Lee DK, Cheng R, Rauser L, Lee SP, Lynch KR, Roth BL, O'Dowd BF . Discovery of a novel member of the histamine receptor family . Molecular Pharmacology . 59 . 3 . 427–433 . March 2001 . 11179435 . 10.1124/mol.59.3.427 . 11 December 2019 . live . https://web.archive.org/web/20210827213636/https://cdr.lib.unc.edu/concern/articles/b2773x653 . 27 August 2021 .
  102. Stanton T, Bolden-Watson C, Cusack B, Richelson E . Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics . Biochemical Pharmacology . 45 . 11 . 2352–2354 . June 1993 . 8100134 . 10.1016/0006-2952(93)90211-e .
  103. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO . Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro . Schizophrenia Research . 37 . 1 . 107–122 . May 1999 . 10227113 . 10.1016/s0920-9964(98)00146-7 . 19891653 .
  104. Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JF . 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs . Proceedings of the National Academy of Sciences of the United States of America . 83 . 22 . 8784–8788 . November 1986 . 2877462 . 387016 . 10.1073/pnas.83.22.8784 . free . 1986PNAS...83.8784W .
  105. Werling LL, Keller A, Frank JG, Nuwayhid SJ . A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder . Experimental Neurology . 207 . 2 . 248–257 . October 2007 . 17689532 . 10.1016/j.expneurol.2007.06.013 . 38476281 .
  106. Jo SH, Youm JB, Lee CO, Earm YE, Ho WK . Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline . British Journal of Pharmacology . 129 . 7 . 1474–1480 . April 2000 . 10742304 . 1571977 . 10.1038/sj.bjp.0703222 .
  107. Yamakawa Y, Furutani K, Inanobe A, Ohno Y, Kurachi Y . Pharmacophore modeling for hERG channel facilitation . Biochemical and Biophysical Research Communications . 418 . 1 . 161–166 . February 2012 . 22244872 . 10.1016/j.bbrc.2011.12.153 .
  108. Fu L, Wang S, Wang X, Wang P, Zheng Y, Yao D, Guo M, Zhang L, Ouyang L . Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer . Scientific Reports . 6 . 1 . 3 . December 2016 . 28442756 . 5431371 . 10.1038/s41598-016-0007-2 .
  109. Jang SW, Liu X, Chan CB, Weinshenker D, Hall RA, Xiao G, Ye K . Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity . Chemistry & Biology . 16 . 6 . 644–656 . June 2009 . 19549602 . 2844702 . 10.1016/j.chembiol.2009.05.010 .
  110. Horishita T, Yanagihara N, Ueno S, Okura D, Horishita R, Minami T, Ogata Y, Sudo Y, Uezono Y, Sata T, Kawasaki T . Antidepressants inhibit Nav1.3, Nav1.7, and Nav1.8 neuronal voltage-gated sodium channels more potently than Nav1.2 and Nav1.6 channels expressed in Xenopus oocytes . Naunyn-Schmiedeberg's Archives of Pharmacology . 390 . 12 . 1255–1270 . December 2017 . 28905186 . 10.1007/s00210-017-1424-x . 23385313 .
  111. Atkin TA, Maher CM, Gerlach AC, Gay BC, Antonio BM, Santos SC, Padilla KM, Rader J, Krafte DS, Fox MA, Stewart GR, Petrovski S, Devinsky O, Might M, Petrou S, Goldstein DB . A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy . Epilepsia . 59 . 4 . 802–813 . April 2018 . 29574705 . 10.1111/epi.14037 . 4478321 . free .
  112. Nau C, Seaver M, Wang SY, Wang GK . Block of human heart hH1 sodium channels by amitriptyline . The Journal of Pharmacology and Experimental Therapeutics . 292 . 3 . 1015–1023 . March 2000 . 10688618 .
  113. Punke MA, Friederich P . Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels . Anesthesia and Analgesia . 104 . 5 . 1256–64, tables of contents . May 2007 . 17456683 . 10.1213/01.ane.0000260310.63117.a2 . 15 October 2009 . live . 21924741 . free . https://web.archive.org/web/20210827213624/https://journals.lww.com/anesthesia-analgesia/pages/default.aspx . 27 August 2021 .
  114. Villatoro-Gómez K, Pacheco-Rojas DO, Moreno-Galindo EG, Navarro-Polanco RA, Tristani-Firouzi M, Gazgalis D, Cui M, Sánchez-Chapula JA, Ferrer T . Molecular determinants of Kv7.1/KCNE1 channel inhibition by amitriptyline . Biochemical Pharmacology . 152 . 264–271 . June 2018 . 29621539 . 10.1016/j.bcp.2018.03.016 . 4929937 .
  115. McClure EW, Daniels RN . Classics in Chemical Neuroscience: Amitriptyline . ACS Chemical Neuroscience . 12 . 3 . 354–362 . February 2021 . 33438398 . 10.1021/acschemneuro.0c00467 . 231596860 .
  116. Schulz P, Dick P, Blaschke TF, Hollister L . Discrepancies between pharmacokinetic studies of amitriptyline . Clinical Pharmacokinetics . 10 . 3 . 257–268 . 1985 . 3893842 . 10.2165/00003088-198510030-00005 . 41881790 .
  117. Nordin C, Bertilsson L . Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline . Clinical Pharmacokinetics . 28 . 1 . 26–40 . January 1995 . 7712660 . 10.2165/00003088-199528010-00004 . 38046048 .
  118. Bryson HM, Wilde MI . Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states . Drugs & Aging . 8 . 6 . 459–476 . June 1996 . 8736630 . 10.2165/00002512-199608060-00008 . 22923577 .
  119. Web site: Pamelor, Aventyl (nortriptyline) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. 2 December 2013. live. https://web.archive.org/web/20131203024651/http://reference.medscape.com/drug/pamelor-nortriptyline-342944#showall. 3 December 2013.
  120. Dawlilng S, Lynn K, Rosser R, Braithwaite R . The pharmacokinetics of nortriptyline in patients with chronic renal failure . British Journal of Clinical Pharmacology . 12 . 1 . 39–45 . July 1981 . 7248140 . 1401753 . 10.1111/j.1365-2125.1981.tb01852.x .
  121. Schulz P, Balant-Gorgia AE, Kubli A, Gertsch-Genet C, Garrone G . Elimination and pharmacological effects following single oral doses of 50 and 75 mg of amitriptyline in man . Archiv für Psychiatrie und Nervenkrankheiten . 233 . 6 . 449–455 . 1983 . 6667101 . 10.1007/BF00342785 . 20844722 .
  122. Web site: Amitriptyline . drugbank.ca . 29 January 2019 . 30 January 2019 . https://web.archive.org/web/20190130053200/https://www.drugbank.ca/drugs/DB00321 . live .
  123. Book: Sadock BJ, Sadock VA . Kaplan & Sadock's Concise Textbook of Clinical Psychiatry. Lippincott Williams & Wilkins. 2008. 978-0-7817-8746-8. 18–. https://web.archive.org/web/20170708005933/https://books.google.com/books?id=ubG51n2NgfwC. 8 July 2017. live.
  124. Orsulak PJ . Therapeutic monitoring of antidepressant drugs: guidelines updated . Therapeutic Drug Monitoring . 11 . 5 . 497–507 . September 1989 . 2683251 . 10.1097/00007691-198909000-00002 .
  125. Rudorfer MV, Potter WZ . Metabolism of tricyclic antidepressants . Cellular and Molecular Neurobiology . 19 . 3 . 373–409 . June 1999 . 10319193 . 10.1023/A:1006949816036 . 7940406 .
  126. Stingl JC, Brockmöller J, Viviani R . Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function . Molecular Psychiatry . 18 . 3 . 273–287 . March 2013 . 22565785 . 10.1038/mp.2012.42 . 20888081 .
  127. Kirchheiner J, Seeringer A . Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes . Biochimica et Biophysica Acta (BBA) - General Subjects . 1770 . 3 . 489–494 . March 2007 . 17113714 . 10.1016/j.bbagen.2006.09.019 .
  128. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC . Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants . Clinical Pharmacology and Therapeutics . 93 . 5 . 402–408 . May 2013 . 23486447 . 3689226 . 10.1038/clpt.2013.2 . 4 November 2018 . live . https://web.archive.org/web/20210827213631/https://deepblue.lib.umich.edu/bitstream/handle/2027.42/109971/cptclpt20132.pdf;jsessionid=2C1238337B5AD4C28DEA9617A364BC2D?sequence=1 . 27 August 2021 .
  129. Book: Medical Genetics Summaries . Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype . https://www.ncbi.nlm.nih.gov/books/NBK425165/ . Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, Malheiro AJ . 6 . National Center for Biotechnology Information (NCBI) . 2017 . 28520380 . Bookshelf ID: NBK425165 . Dean L . 6 February 2020 . 26 October 2020 . https://web.archive.org/web/20201026145821/https://www.ncbi.nlm.nih.gov/books/NBK61999/ . live .
  130. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ . Pharmacogenetics: from bench to byte--an update of guidelines . Clinical Pharmacology and Therapeutics . 89 . 5 . 662–673 . May 2011 . 21412232 . 10.1038/clpt.2011.34 . 2475005 .
  131. The Pharmaceutical Codex. 1994. Principles and practice of pharmaceutics, 12th edn. Pharmaceutical press
  132. Hansch C, Leo A, Hoekman D. 1995. Exploring QSAR.Hydrophobic, electronic and steric constants. Washington, DC: American Chemical Society.
  133. Box KJ, Völgyi G, Baka E, Stuart M, Takács-Novák K, Comer JE . Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution--a validation study . Journal of Pharmaceutical Sciences . 95 . 6 . 1298–1307 . June 2006 . 16552741 . 10.1002/jps.20613 .
  134. Book: Healy D . 1997 . The Antidepressant Era . Harvard University Press . 74–76 . 0674039572 .
  135. Book: Healy D . 1999 . The Psychopharmacologists II . Arnold . 565–566 . 1860360106 .
  136. Web site: The Sopranos Fan's Guide to The Many Saints of Newark. Press J. Vanity Fair. Livia is already troubled enough in the yesteryear of Many Saints that her doctor wants to prescribe her the antidepressant Elavil, but she rejects it. "I'm not a drug addict!" she sneers. Tony pores over the Elavil pamphlet with great interest and even schemes with Dickie Moltisanti to get his suffering mother to take it: "It could make her happy.". 10 January 2021. 10 January 2021. 1 October 2021. https://web.archive.org/web/20211001210620/https://www.vanityfair.com/hollywood/2021/10/many-saints-of-newark-the-sopranos-easter-eggs. live.
  137. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . 14 November 2014. Springer. 978-1-4757-2085-3. 889– . live. https://web.archive.org/web/20170908171129/https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA889 . 8 September 2017.
  138. Book: Index Nominum 2000: International Drug Directory. 2000. Taylor & Francis . 978-3-88763-075-1. 48–.
  139. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012. Springer Science & Business Media. 978-94-011-4439-1. 15–. live. https://web.archive.org/web/20170215043620/https://books.google.com/books?id=tsjrCAAAQBAJ. 15 February 2017.
  140. Web site: Amitriptyline . Drugs.com. 13 August 2017 . live . https://web.archive.org/web/20170813151219/https://www.drugs.com/international/amitriptyline.html . 13 August 2017 .
  141. Jack RH, Hollis C, Coupland C, Morriss R, Knaggs RD, Butler D, Cipriani A, Cortese S, Hippisley-Cox J . Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: A population-based cohort study . PLOS Medicine . 17 . 7 . e1003215 . July 2020 . 32697803 . 7375537 . 10.1371/journal.pmed.1003215 . Hellner C . free .
  142. Flament MF, Bissada H, Spettigue W . Evidence-based pharmacotherapy of eating disorders . The International Journal of Neuropsychopharmacology . 15 . 2 . 189–207 . March 2012 . 21414249 . 10.1017/S1461145711000381 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Amitriptyline".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.